The pathogenesis of hereditary hæmophilia

Tissue Factor Activity in Lymphocyte Cultures from Normal Individuals and Patients with Hemophilia A

“…It has been known since 1911 that both normal and leukemic white cells contain material that enhanced in vitro clotting (3)(4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(14), and recent studies have demonstrated this material to be tissue factor Received for publication 27 November 1972 and in revised form 29 January 1973. 'Abbrevations used in this paper: AHF, antihemophilic factor; CNP, control normal plasma; IBS, imadazole-saline buffer; PHA, phytohemagglutinin; PPD, purified protein derivative of tubercle bacillus; PTT, partial thromboplastin time; SBB, saline-barbital buffer. (15)(16)(17)(18)(19).…”

Hemophilia. I. The Abnormal Coagulation of the Blood and Its Relation to the Blood Platelets

“…Convincing objections to the older theories of Wright (1), Sahli (2), P-mile-Weil (3), Nolf and Herry (4) and Morawitz and Lossen (5) were presented in the excellent paper by Addis (6). A copious bibliography was also included in more recent articles by Minot and Lee (7), Hurwitz and Lucas (8) and Christie, Davies and Stewart (9).…”

Molecular approaches for improved clotting factors for hemophilia

“…Although thought to be the more common factor VIII (FVIII) deficiency, it was recently found posthumously that Queen Victoria had factor IX (FIX) deficiency. 4 The modern era of hemophilia treatment began with the detection of FVIII in human plasma in 1911 5 and the description of its role in hemostasis in 1937. 6 With increasing mechanistic insight into blood coagulation, replacement became more sophisticated, first with the use of plasma in the 1940s, then the development of plasma concentrates in the 1950s, the fractionation of cryoprecipitate in the mid-1960s, and finally the preparation of freeze-dried FVIII that was suitable for storage and use at home in 1968.…”